A Phase 3 interventional study of Iron isomaltoside/ferric derisomaltose and Ferric carboxymaltose in Iron Deficiency Anaemia and Iron Deficiency Anemia, sponsored by Pharmacosmos A/S. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-25.
Sponsored by Pharmacosmos A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency — 9 open to participants now, 9 under way, 4 of them phase 3. iron isomaltoside 1000 · Anemia, Iron-Deficiency.
Among the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, this one is the 15th largest by enrollment, is one of 5 that started in 2017, is one of 18 in phase 3, and was the 14th registered.
601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.
Browse Anemia, Iron-Deficiency studies →9 of the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency are open now, in 6 countries. Recruiting first, the newest first:
Sichuan Huiyu Pharmaceutical Co., Ltd · Sites in China
Ages 18+
Hull University Teaching Hospitals NHS Trust · Sites in United Kingdom
Ages 18+
AHS Cancer Control Alberta · Sites in Canada
Ages 18+ · Women only
Children's Hospital Los Angeles · Sites in United States
Ages 16–60 · Women only · Healthy volunteers
Sun Yat-sen University · Sites in China
Ages 18–65
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 19 · Phase 4 7
First in 2007; this study’s year is marked. 5 started in 2017.
This study's enrollment of 123 is above the median of 100 across 460 interventional studies indexed under Anemia, Iron-Deficiency.
Median enrollment 121 across the 32 interventional studies. Of the 19 that completed or were terminated, 8 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 32 have an industry lead sponsor. The 10 most frequent:
Pharmacosmos A/S is the lead sponsor of 36 studies on the registry; 5 are open to participants now.
15 studies in Anemia, Iron-Deficiency by Pharmacosmos A/S: none open now, none under way, none of them phase 3. Of 14 finished, 7 (50%) have results posted.
Among the 15 studies in Anemia, Iron-Deficiency by Pharmacosmos A/S, this one is the 8th largest by enrollment of the 13 interventional ones that give a count, is one of 5 that started in 2017, is one of 11 in phase 3, and was the 14th registered.
Pharmacosmos A/S’s Anemia, Iron-Deficiency studies by the year they started, since 2007.
3 of the studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05462704Phase 3Women and Infants Hospital of Rhode IslandIntravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy | 2027-03-30 |
| NCT06884280Phase 3Hull University Teaching Hospitals NHS TrustComparing High and Low Dose Iron Treatments for People on Peritoneal Dialysis: The PALaDIN Study | 2027-10 |
| NCT04913649dr. P. NoordzijIntravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patients | 2026-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, from their registry updates:
Among Pharmacosmos A/S’s 15 in Anemia, Iron-Deficiency:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The trial was designed to evaluate the incidence of unintended hypophosphatemia (low level of phosphate in the blood) in subjects with iron deficiency anaemia (IDA).
This trial was designed to evaluate the effect of IV iron isomaltoside/ferric derisomaltose compared with IV ferric carboxymaltose on s-phosphate in subjects with IDA caused by different etiologies.
The subjects received either a single intravenous (IV) dose of iron isomaltoside/ferric derisomaltose (1000 mg at baseline) or two IV doses of ferric carboxymaltose (one dose 750 mg at baseline and a second dose 750 mg on day 7; cumulative dose: 1500 mg). The study subjects were monitored for up to 35 days from baseline.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered IV
Drug: Iron isomaltoside/ferric derisomaltose
Administered IV
Drug: Ferric carboxymaltose
Drug page: Iron isomaltoside 1000
Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial. The dose of iron isomaltoside/ferric derisomaltose for the individual subject was a single IV infusion of 1000 mg (10 mL containing 1000 mg iron isomaltoside/ferric derisomaltose diluted in 100 mL 0.9 % sodium chloride), given over approximately 20 minutes (50 mg iron/min) at baseline (cumulative dose: 1000 mg).
Also known as: Monofer®, Monoferric®, Monover®, Monofar®, Monoferro®
Ferric carboxymaltose (Injectafer®; 50 mg/mL) was the comparator in this trial. Ferric carboxymaltose was administered as 750 mg, infused over at least 15 minutes at baseline and on day 7 (cumulative dose: 1500 mg).
Also known as: Injectafer®, Ferinject®
Incidence of Hypophosphatemia (S-phosphate Level <2 mg/dL)
Safety The incidence of hypophosphatemia (defined as s-phosphate \<2 mg/dL) at any time from baseline up to day 35.
Time frame: Baseline to day 35
Time With Hypophosphatemia ( S-phosphate Level <2.0 mg/dL)
Safety Time with hypophosphatemia (i.e. time with s-phosphate level \< 2.0 mg/dL) from baseline up to day 35. The time with hypophosphatemia was calculated as the actual number of days from the first day where s-phosphate was \<2 mg/dL until the first day when s-phosphate was ≥2 mg/dL. If the subject did not reach s-phosphate ≥2 mg/dL, the subject was regarded as censored on day 35.
Time frame: Baseline to day 35
Proportion of Subjects With Hypophosphatemia on Day 35 ( S-phosphate Level <2.0 mg/dL)
Safety Evaluate the proportion of subjects with hypophosphatemia (s-phosphate level \<2.0 mg/dL) on day 35.
Time frame: Baseline to day 35
Absolute [∆] Changes in S-phosphate From Baseline to Day 1, 7, 8, 14, 21, and 35
Safety Absolute \[∆\] changes in s-phosphate from baseline to day 1, 7, 8, 14, 21, and 35.
Time frame: Baseline, days 1, 7, 8, 14, 21, and 35
Relative [%] Changes in S-phosphate From Baseline to Day 1, 7, 8, 14, 21, and 35
Safety Relative \[%\] changes in s-phosphate from baseline to day 1, 7, 8, 14, 21, and 35.
Time frame: Baseline, days 1, 7, 8, 14, 21, and 35
Change From Baseline in Fractional Phosphate Urinary Excretion
Safety Change in absolute fractional phosphate urinary excretion from baseline to days 1, 7, 8, 14, 21, and 35. Fractional excretion of phosphate (FEPi) is calculated as (\[phosphate in urine X creatinine in serum\]/\[phosphate in serum X creatinine in urine\]) X 100, and the unit is %.
Time frame: Baseline, days 1, 7, 8, 14, 21, and 35
Change in Concentration of (Intact) Fibroblast Growth Factor 23 (iFGF23) From Baseline to Day 1, 7, 8, 14, 21, and 35
Safety Change in concentration of (Intact) Fibroblast Growth Factor 23 (iFGF23) from baseline to day 1, 7, 8, 14, 21, and 35.
Time frame: Baseline, days 1, 7, 8, 14, 21, and 35
Change in C-terminal Fibroblast Growth Factor 23 (cFGF23) From Baseline to Days 1, 7, 8, 14, 21, and 35
Safety Change in C-terminal Fibroblast Growth Factor 23 (cFGF23) from baseline to days 1, 7, 8, 14, 21, and 35.
Time frame: Baseline, days 1, 7, 8, 14, 21, and 35
Change in Vitamin 25-Hydroxyvitamin D (Vitamin D 25) From Baseline to Days 1, 7, 8, 14, 21, and 35
Safety Change in vitamin 25-Hydroxyvitamin D (vitamin D 25) from baseline to days 1, 7, 8, 14, 21, and 35.
Time frame: Baseline, days 1, 7, 8, 14, 21, and 35
Change in 1,25-Dihydroxyvitamin D (Vitamin D 1.25) From Baseline to Days 1, 7, 8, 14, 21, and 35
Safety Change in 1,25-Dihydroxyvitamin D (vitamin D 1.25) from baseline to days 1, 7, 8, 14, 21, and 35.
Time frame: Baseline, days 1, 7, 8, 14, 21, and 35
Change in 24,25-Dihydroxyvitamin D (Vitamin D 24.25) From Baseline to Days 1, 7, 8, 14, 21, and 35
Safety Change in 24,25-Dihydroxyvitamin D (vitamin D 24.25) from baseline to days 1, 7, 8, 14, 21, and 35
Time frame: Baseline, days 1, 7, 8, 14, 21, and 35
Change in Intact Parathyroid Hormone (PTH) From Baseline to Days 1, 7, 8, 14, 21, and 35
Safety Change in intact Parathyroid hormone (PTH) from baseline to days 1, 7, 8, 14, 21, and 35.
Time frame: Baseline, days 1, 7, 8, 14, 21, and 35
Change in Ionized Calcium From Baseline to Days 1, 7, 8, 14, 21, and 35
Safety Change in ionized calcium from baseline to days 1, 7, 8, 14, 21, and 35.
Time frame: Baseline, days 1, 7, 8, 14, 21, and 35
Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions
Safety For this endpoint, the number of participants with serious or severe hypersensitivity reactions were evaluated.
Time frame: Baseline to day 35
Change in Hemoglobin (Hb) Per Gram Iron From Baseline to Days 1, 7, 8, 14, 21, and 35
Efficacy Change in hemoglobin (Hb) per gram iron from baseline to days 1, 7, 8, 14, 21, and 35.
Time frame: Baseline, days 1, 7, 8, 14, 21, and 35
Change in S-ferritin From Baseline to Days 1, 7, 8, 14, 21, and 35
Efficacy Change in s-ferritin from baseline to days 1, 7, 8, 14, 21, and 35.
Time frame: Baseline, days 1, 7, 8, 14, 21, and 35
Change in Transferrin Saturation (TSAT) From Baseline to Days 1, 7, 8, 14, 21, and 35
Efficacy Change in Transferrin Saturation (TSAT) from baseline to days 1, 7, 8, 14, 21, and 35. TSAT is the value of serum iron divided by the total iron-binding capacity and the unit is %, which referrers to % of iron-binding sites of transferrin being occupied by iron.
Time frame: Baseline, days 1, 7, 8, 14, 21, and 35
A total of 310 subjects were screened and 123 subjects were randomised into the trial.
| Milestone | Iron Isomaltoside/Ferric Derisomaltose | Ferric Carboxymaltose |
|---|---|---|
| Started | 62 | 61 |
| Safety analysis set | 63 | 60 |
| Completed | 59 | 58 |
| Not completed | 3 | 3 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Lost to follow-up | 2 | 1 |
Safety The incidence of hypophosphatemia (defined as s-phosphate \<2 mg/dL) at any time from baseline up to day 35.
| Participants | Iron Isomaltoside/Ferric Derisomaltose | Ferric Carboxymaltose |
|---|---|---|
| Incidence of Hypophosphatemia (S-phosphate Level <2 mg/dL) | 5 | 45 |
Safety Time with hypophosphatemia (i.e. time with s-phosphate level \< 2.0 mg/dL) from baseline up to day 35. The time with hypophosphatemia was calculated as the actual number of days from the first day where s-phosphate was \<2 mg/dL until the first day when s-phosphate was ≥2 mg/dL. If the subject did not reach s-phosphate ≥2 mg/dL, the subject was regarded as censored on day 35.
| days | Iron Isomaltoside/Ferric Derisomaltose | Ferric Carboxymaltose |
|---|---|---|
| Time With Hypophosphatemia ( S-phosphate Level <2.0 mg/dL) | 15 (7 to 56) | 29 (21 to 42) |
Safety Evaluate the proportion of subjects with hypophosphatemia (s-phosphate level \<2.0 mg/dL) on day 35.
| Participants | Iron Isomaltoside/Ferric Derisomaltose | Ferric Carboxymaltose |
|---|---|---|
| Proportion of Subjects With Hypophosphatemia on Day 35 ( S-phosphate Level <2.0 mg/dL) | 1 | 24 |
Safety Absolute \[∆\] changes in s-phosphate from baseline to day 1, 7, 8, 14, 21, and 35.
| mg/dL | Iron Isomaltoside/Ferric Derisomaltose | Ferric Carboxymaltose |
|---|---|---|
| Day 1 | 0.25 ± 0.55 | -0.24 ± 0.61 |
| Day 7 | -0.06 ± 0.75 | -1.15 ± 0.63 |
| Day 8 | -0.10 ± 0.77 | -1.15 ± 0.64 |
| Day 14 | -0.04 ± 0.75 | -1.44 ± 0.83 |
| Day 21 | 0.04 ± 0.69 | -1.02 ± 0.99 |
| Day 35 | 0.24 ± 0.76 | -0.92 ± 0.85 |
Safety Relative \[%\] changes in s-phosphate from baseline to day 1, 7, 8, 14, 21, and 35.
| Percentage change from baseline | Iron Isomaltoside/Ferric Derisomaltose | Ferric Carboxymaltose |
|---|---|---|
| Day 1 | 9.31 ± 18.98 | -5.94 ± 16.59 |
| Day 7 | 0.55 ± 23.15 | -33.68 ± 17.53 |
| Day 8 | -0.95 ± 24.02 | -34.03 ± 17.61 |
| Day 14 | 1.13 ± 25.21 | -42.59 ± 24.81 |
| Day 21 | 2.85 ± 22.66 | -30.11 ± 30.79 |
| Day 35 | 9.69 ± 24.55 | -27.58 ± 27.47 |
Safety Change in absolute fractional phosphate urinary excretion from baseline to days 1, 7, 8, 14, 21, and 35. Fractional excretion of phosphate (FEPi) is calculated as (\[phosphate in urine X creatinine in serum\]/\[phosphate in serum X creatinine in urine\]) X 100, and the unit is %.
| percentage excreted | Iron Isomaltoside/Ferric Derisomaltose | Ferric Carboxymaltose |
|---|---|---|
| Day 1 | -1.73 ± 4.85 | 2.44 ± 5.09 |
| Day 7 | 0.56 ± 8.30 | 8.12 ± 9.16 |
| Day 8 | 1.21 ± 7.71 | 9.08 ± 11.30 |
| Day 14 | 0.10 ± 7.34 | 11.46 ± 13.53 |
| Day 21 | 0.78 ± 9.46 | 9.43 ± 12.33 |
| Day 35 | -1.97 ± 7.29 | 4.90 ± 11.07 |
Safety Change in concentration of (Intact) Fibroblast Growth Factor 23 (iFGF23) from baseline to day 1, 7, 8, 14, 21, and 35.
| pg/mL | Iron Isomaltoside/Ferric Derisomaltose | Ferric Carboxymaltose |
|---|---|---|
| Day 1 | -2.7 ± 28.6 | 103.6 ± 89.5 |
| Day 7 | 6.8 ± 26.9 | 70.3 ± 78.4 |
| Day 8 | 4.9 ± 25.2 | 305.9 ± 262.3 |
| Day 14 | -8.6 ± 25.7 | 106.1 ± 114.9 |
| Day 21 | -0.9 ± 39.7 | 66.7 ± 96.6 |
| Day 35 | -10.5 ± 25.6 | 34.7 ± 64.2 |
Safety Change in C-terminal Fibroblast Growth Factor 23 (cFGF23) from baseline to days 1, 7, 8, 14, 21, and 35.
| RU/mL | Iron Isomaltoside/Ferric Derisomaltose | Ferric Carboxymaltose |
|---|---|---|
| Day 1 | -742.3 ± 800.7 | -390.2 ± 665.7 |
| Day 7 | -723.6 ± 801.6 | -477.5 ± 652.0 |
| Day 8 | -648.9 ± 757.5 | -284.2 ± 638.6 |
| Day 14 | -717.9 ± 798.2 | -401.5 ± 661.5 |
| Day 21 | -678.1 ± 783.5 | -458.9 ± 658.9 |
| Day 35 | -660.1 ± 806.7 | -481.3 ± 653.7 |
Safety Change in vitamin 25-Hydroxyvitamin D (vitamin D 25) from baseline to days 1, 7, 8, 14, 21, and 35.
| ng/mL | Iron Isomaltoside/Ferric Derisomaltose | Ferric Carboxymaltose |
|---|---|---|
| Day 1 | 0.04 ± 2.26 | 0.32 ± 2.26 |
| Day 7 | 0.81 ± 3.34 | -0.94 ± 3.93 |
| Day 8 | 0.32 ± 3.35 | -0.07 ± 5.07 |
| Day 14 | 0.71 ± 5.17 | -1.29 ± 5.14 |
| Day 21 | 0.78 ± 6.03 | -0.90 ± 4.70 |
| Day 35 | -0.24 ± 6.44 | -0.72 ± 4.34 |
Safety Change in 1,25-Dihydroxyvitamin D (vitamin D 1.25) from baseline to days 1, 7, 8, 14, 21, and 35.
| pg/mL | Iron Isomaltoside/Ferric Derisomaltose | Ferric Carboxymaltose |
|---|---|---|
| Day 1 | 5.13 ± 13.05 | -20.57 ± 17.56 |
| Day 7 | -19.92 ± 24.57 | -38.84 ± 20.86 |
| Day 8 | -16.07 ± 25.10 | -39.63 ± 27.11 |
| Day 14 | -3.31 ± 15.93 | -39.04 ± 27.46 |
| Day 21 | -3.37 ± 16.45 | -28.89 ± 30.06 |
| Day 35 | -3.86 ± 20.08 | -17.94 ± 26.15 |
Safety Change in 24,25-Dihydroxyvitamin D (vitamin D 24.25) from baseline to days 1, 7, 8, 14, 21, and 35
| ng/mL | Iron Isomaltoside/Ferric Derisomaltose | Ferric Carboxymaltose |
|---|---|---|
| Day 1 | -0.02 ± 0.41 | 0.13 ± 0.51 |
| Day 7 | 0.30 ± 0.49 | 0.72 ± 0.78 |
| Day 8 | 0.19 ± 0.69 | 0.71 ± 0.84 |
| Day 14 | 0.13 ± 0.60 | 0.95 ± 0.98 |
| Day 21 | 0.12 ± 0.93 | 0.75 ± 0.93 |
| Day 35 | 0.06 ± 0.89 | 0.60 ± 0.99 |
Safety Change in intact Parathyroid hormone (PTH) from baseline to days 1, 7, 8, 14, 21, and 35.
| pg/mL | Iron Isomaltoside/Ferric Derisomaltose | Ferric Carboxymaltose |
|---|---|---|
| Day 1 | -1.3 ± 20.2 | 0.7 ± 21.3 |
| Day 7 | -4.6 ± 26.6 | 7.8 ± 26.6 |
| Day 8 | 1.8 ± 27.9 | 2.6 ± 29.2 |
| Day 14 | 3.2 ± 30.6 | 16.7 ± 33.7 |
| Day 21 | -3.1 ± 22.8 | 17.2 ± 34.9 |
| Day 35 | 0.2 ± 27.9 | 22.1 ± 41.2 |
Safety Change in ionized calcium from baseline to days 1, 7, 8, 14, 21, and 35.
| mg/dL | Iron Isomaltoside/Ferric Derisomaltose | Ferric Carboxymaltose |
|---|---|---|
| Day 1 | 0.04 ± 0.18 | 0.00 ± 0.20 |
| Day 7 | 0.02 ± 0.16 | -0.07 ± 0.22 |
| Day 8 | 0.03 ± 0.19 | -0.03 ± 0.20 |
| Day 14 | 0.02 ± 0.22 | -0.08 ± 0.22 |
| Day 21 | 0.08 ± 0.19 | -0.03 ± 0.21 |
| Day 35 | 0.02 ± 0.21 | -0.03 ± 0.20 |
Safety For this endpoint, the number of participants with serious or severe hypersensitivity reactions were evaluated.
| Participants | Iron Isomaltoside/Ferric Derisomaltose | Ferric Carboxymaltose |
|---|---|---|
| Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions | 1 | 0 |
Efficacy Change in hemoglobin (Hb) per gram iron from baseline to days 1, 7, 8, 14, 21, and 35.
| g/dL per g of iron | Iron Isomaltoside/Ferric Derisomaltose | Ferric Carboxymaltose |
|---|---|---|
| Day 1 | -0.16 ± 1.29 | 0.28 ± 1.82 |
| Day 7 | 0.65 ± 0.86 | 0.94 ± 1.49 |
| Day 8 | 0.50 ± 1.14 | 0.64 ± 0.81 |
| Day 14 | 1.55 ± 1.53 | 1.16 ± 0.90 |
| Day 21 | 1.68 ± 1.40 | 1.44 ± 0.97 |
| Day 35 | 2.16 ± 1.62 | 1.94 ± 1.02 |
Efficacy Change in s-ferritin from baseline to days 1, 7, 8, 14, 21, and 35.
| ng/mL | Iron Isomaltoside/Ferric Derisomaltose | Ferric Carboxymaltose |
|---|---|---|
| Day 1 | 82.0 ± 58.3 | 94.7 ± 62.4 |
| Day 7 | 261.7 ± 184.2 | 289.5 ± 173.0 |
| Day 8 | 248.1 ± 182.4 | 325.8 ± 220.1 |
| Day 14 | 133.9 ± 109.9 | 352.9 ± 223.4 |
| Day 21 | 97.2 ± 127.6 | 179.2 ± 135.0 |
| Day 35 | 46.8 ± 63.0 | 108.9 ± 107.3 |
Efficacy Change in Transferrin Saturation (TSAT) from baseline to days 1, 7, 8, 14, 21, and 35. TSAT is the value of serum iron divided by the total iron-binding capacity and the unit is %, which referrers to % of iron-binding sites of transferrin being occupied by iron.
| percentage of saturation | Iron Isomaltoside/Ferric Derisomaltose | Ferric Carboxymaltose |
|---|---|---|
| Day 1 | 118.9 ± 52.0 | 85.7 ± 40.4 |
| Day 7 | 10.2 ± 34.8 | 12.9 ± 11.2 |
| Day 8 | 6.3 ± 34.7 | 61.2 ± 43.0 |
| Day 14 | 4.8 ± 32.6 | 16.4 ± 11.3 |
| Day 21 | 6.8 ± 31.1 | 16.6 ± 11.7 |
| Day 35 | 3.1 ± 32.3 | 14.7 ± 10.8 |
Safety Incidence of hypophosphatemia (defined as s-phosphate level ≤1 mg/dL) at any time from baseline up to day 35.
| Participants | Iron Isomaltoside/Ferric Derisomaltose | Ferric Carboxymaltose |
|---|---|---|
| Incidence of S-phosphate Level ≤1.0 mg/dL at Any Time From Baseline to Day 35 | 0 | 7 |
Collected over From the time subjects signed the informed consent form (CRF) and until they completed the study, all adverse events (AEs) or serious adverse events (SAEs) were reported in the CRF. The actual study duration was 35 days (or shorted if the trial was discontinued). Overall, eligible subjects participated in the trial for approximately 9 weeks (including a 28-day screening period).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Iron Isomaltoside/Ferric Derisomaltose | 0/63 (0%) | 1/63 (1.6%) | 0/63 (0%) |
| Ferric Carboxymaltose | 0/60 (0%) | 0/60 (0%) | 25/60 (41.7%) |
| Event | Iron Isomaltoside/Ferric Derisomaltose | Ferric Carboxymaltose |
|---|---|---|
| HypersensitivityImmune system disorders | 1/63 | 0/60 |
| Event | Iron Isomaltoside/Ferric Derisomaltose | Ferric Carboxymaltose |
|---|---|---|
| Blood phosphorus decreasedInvestigations | 0/63 | 13/60 |
| HypophosphatemiaMetabolism and nutrition disorders | 0/63 | 12/60 |
| NauseaGastrointestinal disorders | 0/63 | 4/60 |
| Age, Categorical(Participants) | Iron Isomaltoside/Ferric Derisomaltose | Ferric Carboxymaltose | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 60 | 54 | 114 |
| >=65 years | 3 | 6 | 9 |
| Age, Continuous(years) | Iron Isomaltoside/Ferric Derisomaltose | Ferric Carboxymaltose | Total |
|---|---|---|---|
| Mean | 43.9 ± 10.4 | 46.3 ± 11.6 | 45.1 ± 11.0 |
| Sex: Female, Male(Participants) | Iron Isomaltoside/Ferric Derisomaltose | Ferric Carboxymaltose | Total |
|---|---|---|---|
| Female | 61 | 57 | 118 |
| Male | 2 | 3 | 5 |
| Ethnicity (NIH/OMB)(Participants) | Iron Isomaltoside/Ferric Derisomaltose | Ferric Carboxymaltose | Total |
|---|---|---|---|
| Hispanic or Latino | 37 | 36 | 73 |
| Not Hispanic or Latino | 26 | 24 | 50 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Iron Isomaltoside/Ferric Derisomaltose | Ferric Carboxymaltose | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 22 | 19 | 41 |
| White | 38 | 38 | 76 |
| More than one race | 1 | 2 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Iron Isomaltoside/Ferric Derisomaltose | Ferric Carboxymaltose | Total |
|---|---|---|---|
| Black/American Indian | 0 | 1 | 1 |
| White/American Indian | 1 | 1 | 2 |
| Region of Enrollment(participants) | Iron Isomaltoside/Ferric Derisomaltose | Ferric Carboxymaltose | Total |
|---|---|---|---|
| United States | 63 | 60 | 123 |
| Iron Deficiency Anaemia (IDA) due to gynaecological blood loss(Participants) | Iron Isomaltoside/Ferric Derisomaltose | Ferric Carboxymaltose | Total |
|---|---|---|---|
| Yes | 41 | 42 | 83 |
| No | 22 | 18 | 40 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2017 to primary completion in Jun 2018, 7 months.
Results were first posted in Feb 2020, 1 year 8 months after primary completion. A results delay was requested in May 2019.
Of 49 phase 3 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 7 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iron isomaltoside 1000